Editors' ChoiceCancer

Correcting COMPASS dysfunction in cancer

See allHide authors and affiliations

Science Translational Medicine  06 Jun 2018:
Vol. 10, Issue 444, eaau0466
DOI: 10.1126/scitranslmed.aau0466

You are currently viewing the abstract.

View Full Text

Abstract

An EZH2 inhibitor can be potentially used as an effective therapy for cancers with COMPASS-component mutations.

View Full Text